These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33077259)

  • 1. Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Ceppi L; Grassi T; Galli F; Buda A; Aletti G; Lissoni AA; Adorni M; Garbi A; Colombo N; Bonazzi C; Landoni F; Fruscio R
    Gynecol Oncol; 2021 Jan; 160(1):64-70. PubMed ID: 33077259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
    J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian Carcinoma: A Single-Centre Eight-Year Case-Series Study with Survival Analysis.
    Subtirelu GD; Steriu A; Bratucu E
    Chirurgia (Bucur); 2024 Aug; 119(4):373-384. PubMed ID: 39250607
    [No Abstract]   [Full Text] [Related]  

  • 8. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.
    Porter JM; McFarlane I; Bartos C; Churchman M; May J; Herrington CS; Connolly KC; Ryan NAJ; Hollis RL
    JNCI Cancer Spectr; 2024 Jul; 8(4):. PubMed ID: 38902938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
    Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
    Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
    Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Nasioudis D; Latif NA; Simpkins F; Cory L; Giuntoli RL; Haggerty AF; Morgan MA; Ko EM
    Gynecol Oncol; 2020 Feb; 156(2):315-319. PubMed ID: 31839340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
    Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
    Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary epithelial ovarian carcinoma in Taiwanese women.
    Wang PH; Yuan CC; Juang CM; Lai CR; Yen MS; Chao HT; Ng HT
    Eur J Gynaecol Oncol; 2001; 22(1):57-60. PubMed ID: 11321496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
    Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.